CDC panel recommends Pfizer, Moderna vaccines over J&J attributable to uncommon blood clot circumstances

A health care worker holds a dose of the Johnson & Johnson vaccine.

Phill Magakoe | AFP | Getty Images

An advisory board for the Centers for Disease Control and Prevention on Thursday recommended Pfizer and Modern‘s vaccines over Johnson & Johnson‘s shot for adults ages 18 and up after dozens of people found a rare blood clot after the J&J vaccination, all of whom were hospitalized and nine of them died.

The Advisory Committee on Immunization Practices has unanimously decided to recommend Pfizer and Moderna over the Johnson & Johnson vaccine. CDC director Rochelle Walensky has yet to accept the recommendation.

The CDC has confirmed 54 cases of people who develop blood clots and have low blood platelet levels, a new condition known as thrombosis with thrombocytopenia syndrome that mainly affects younger women. All patients were hospitalized, nine people died and 36 were treated in the intensive care unit.

The US has administered more than 17 million J&J doses since the Food and Drug Administration approved the emergency syringe in February.

“TTS case reporting rates after Janssen vaccines are higher in men and women in a wider age range than previous estimates,” said Dr. Keipp Talbot, chairman of the CDC’s vaccines and safety subgroup, the advisory body.

Although the panel’s recommendation was unanimous, some members struggled with the vote. The CDC experts could also have recommended giving up the shot altogether or restricting it to certain age or demographic groups.

Dr. Pablo Sanchez, a professor of pediatrics at Ohio State University, said he was not recommending J&J admission to any of his patients, despite ultimately standing for the panel’s proposal.

“I just can’t recommend a vaccine associated with a disease that can lead to death,” Sanchez told the committee. “I don’t recommend it to any of my patients’ parents.”

Seven of the patients who died were women and two men, with a mean age of 45 years. Most of the deceased had previous health conditions such as obesity, high blood pressure and diabetes. The death reporting rate was 0.57 deaths per million doses administered, according to the CDC.

“In reviewing these cases, we noticed how quickly patient status deteriorates and leads to death,” said Dr. Isaac See of the CDC’s Vaccine Safety Team joined the advisory board.

According to the CDC, patients typically developed symptoms 9 days after vaccination and were hospitalized 5 days after symptoms appeared. The overwhelming majority of patients were women, 37 total, and the mean age was 44. Seventeen men developed TTS.

Johnson & Johnson’s director of global therapeutic vaccines Penny Heaton defended the company’s shot during the meeting, saying it “saves lives here in the US and on every continent around the world”.

“It’s easy to store and transport,” said Heaton. “In many low- and middle-income countries, our vaccine is the primary and sometimes even the only option in the US as its permanent protection may be the preferred choice for people who cannot or do not want to return for multiple vaccinations.”

Heaton said J&J recognizes the incidents of TTS related to the vaccine and that the condition can be fatal, although cases are rare. She said patient safety and wellbeing remain a top priority for J&J, and the company has several studies underway to identify risk factors related to developing TTS.

In April, the Food and Drug Administration and the CDC stopped briefly the use of the Johnson & Johnson single vaccine after six adult women developed blood clots and low platelet counts at the same time.

A week later, the FDA and the CDC did canceled the break on J&J shots after the independent advisory panel said the benefits of the shots outweigh the risks. At the time, the panel did not recommend restricting admissions based on age or gender. It suggested that the FDA put a warning label on for women under 50.

The FDA has advised health care providers not to give a J&J booster to people who have developed TTS in the past after the first injection. The FDA also said the J&J syringe should not be given to people who received the vaccine from AstraZeneca, even though AstraZeneca is not approved for use in the United States

CDC experts said Thursday that people who received J&J booster doses have not seen any cases of TTS, although the number of boosters is relatively small.

“Currently available evidence supports a causal relationship between TTS and the Janssen COVID-19 vaccine,” the FDA said in the factsheet for healthcare providers.

In October, the FDA and CDC approved authorized J&J boosters for all adults at least two months after receiving their first J&J syringe. More than 800,000 people have received J&J boosters, according to CDC data. People who received their primary vaccination with the J&J shot can also be boosted with the Pfizer or Moderna vaccines.

This is the latest news. Please check again for updates.

FDA panel unanimously recommends Moderna Covid booster pictures for at-risk adults

A key advisory committee to the Food and Drug Administration unanimously recommended Thursday that booster shots be taken from ModernCovid-19 vaccine for people 65 and older and other Americans at risk. The vote was a critical step before the US can begin giving third vaccinations to some of the more than 69 million people who originally received this vaccine.

The non-binding decision of the Advisory Committee on Vaccines and Allied Biological Products of the FDA would extend the guidelines for Moderna with the third recordings of the FDA PfizerBioNTech Vaccination. These recordings were authorized less than a month ago to a wide range of Americans, including the elderly, adults with pre-existing medical conditions, and those who work or live in high-risk environments such as healthcare and grocery stores.

Although the agency has not always followed the advice of its committee, it often does. A final FDA decision on Moderna boosters could be made within days. A CDC Vaccines Advisory Committee is then expected to vote on the FDA’s proposal next week. If it recommends approval and the CDC endorses it, eligible Americans who completed their vaccinations at least six months ago could begin booster vaccinations immediately.

Booster vaccination has been a controversial issue for scientists – inside and outside of government – especially since many people in the US and other parts of the world have not yet received a single dose of a vaccine. The World Health Organization is urging wealthy countries to wait before distributing boosters, and some scientists say they are not convinced that most Americans need boosters right now.

When the FDA committee met last month, they opposed a proposal to distribute booster vaccines from Pfizer and BioNTech to the general public. Some committee members said at the time they were concerned that there wasn’t enough data to make a recommendation, while others argued that third shots should be restricted to specific groups.

After Moderna’s unanimous vote on Thursday, committee member Dr. Patrick Moore said the data the company submitted for approval of a booster was “not well explained,” adding that he was more on “gut instinct”.

“The data itself is not strong, but it is certainly going in a direction that supports this vote,” he said.

Some members said the boosters should prevent what they call breakthrough infections, which they believe are critical to protecting healthcare facilities from being overloaded, while other members said the third vaccinations should ensure high-risk patients don’t have serious illnesses. Some committee members also suggested that young people might not need boosters as the first few shots in these groups still persist.

Dr. Another member, Paul Offit, stressed that most people who received the first two doses of Moderna’s vaccine are still well protected and hopes the recommendation doesn’t send the “wrong message” to the public.

“If we’re trying to prevent the inevitable, which is a decline in neutralizing antibodies and an erosion of protection against mild or asymptomatic infections, that’s a high bar that we don’t hold any other vaccine by,” he told his colleagues.

The Biden government hopes the extra dose will provide long-term and permanent protection for the US population from serious illness, hospitalization, and death as the fast-paced Delta variant continues to spread.

Dr. Peter Marks, the FDA’s chief vaccine regulator, reached the committee Thursday before the vote, telling the panel of experts that the agency is promoting “all the different viewpoints” on the “complex and evolving” data.

“However, I would ask you, as we move forward, to do our best to focus our reflections on the science related to the proposal under consideration today and not on operational issues related to a booster campaign or related issues global vaccine justice. ”he added.

Moderna filed for FDA approval of a booster dose on September 1. The company said the results are based on a clinical study of about 170 adults, fewer than the 318 people screened for Pfizer’s booster vaccination. Moderna said a third half-dose shot – 50 micrograms – was safe for the first two injections and produced a strong immune response.

Once approved, the company plans to send a letter to health care providers explaining the dose difference for the third injection, said Dr. Jacqueline Miller, the company’s director of infection research, during a presentation Thursday.

The side effects of Moderna boosters were similar to those after the second dose, the company wrote in a document released Tuesday by the FDA. Most of the side effects were of minor severity and Moderna reported no cases of rare heart inflammation, myocarditis, or pericarditis in subjects for up to 29 days after receiving the booster.

Before recommending the third shots, the panel listened to several presentations, including from Israeli health officials, who began to offer boosters to their populations before many other countries. The country has mainly used Pfizer’s vaccine, but some Moderna boosters have been given.

Israel has given 3.7 million third vaccinations since its booster campaign began in late July, with about a third of the extra vaccinations going to people aged 60 and over, Sharon Alroy Price, director of public health at Israel’s Ministry of Health, told the panel.

She presented data suggesting that people receiving a booster dose are less likely to get infected with Covid or become seriously ill. She said officials have so far identified 17 cases of myocarditis or pericarditis after third doses.

“I think we can say, if we look at all of the data in Israel so far, that the use of booster doses has helped Israel reduce the infections and the severe cases,” she said.

– CNBC’s Robert Towey contributed to this report.

Fauci defends FDA panel determination to reject third doses for all People

The leading expert on infectious diseases, Dr. Anthony Fauci, responds to allegations made by Senator Rand Paul (R-KY) as he testifies before the Senate Health, Education, Labor, and Pensions Committee on Capitol Hill in Washington, DC on July 20, 2021.

J. Scott Applewhite | Swimming pool | Reuters

Dr. Anthony Fauci defended the Decision of the Board of the Food and Drug Administration refuse to offer a third booster shot PfizerBioNTech Covid-19 vaccine for the general US population.

“I don’t think you made a mistake,” the White House chief medical officer told CNN’s State of the Union on Sunday.

Fauci added that he would support a third dose if future data shows it is effective. As the FDA continues to gather new information about boosters, persuading unvaccinated Americans to get vaccinated remains a priority.

Fauci’s comments come after the FDA advisory committee on Friday Voted against giving third shots of Pfizer’s Covid-19 vaccine to all Americans, although she recommended booster doses for people aged 65 and over and those with underlying medical conditions.

The FDA panel’s decision added to the confusion over the booster dose after President Joe Biden said last month that boosters would be available to all Americans starting the week of September 20th.

“I understand why there might be confusion because I think people have not understood the difference between planning something and actually not understanding what element of it, what portion of it is actually being introduced, and that’s exactly what happened,” he said “Meet the Press” from NBC.

He later told ABC’s This Week that the government had set the September 20 deadline as a wildcard, depending on input from the FDA and the Centers for Disease Control and Prevention.

“The plan was that we have to be ready to do this as soon as a decision is made,” he said. “And when you have a plan, put a date on it and say, ‘We want to be able to prepare for the week of September 20th'” “

Current data from Israel indicates the effectiveness of the vaccine As time decreases, a third shot of Pfizer could restore infection protection to 95% six months after a second dose.

As of September 18, more than 181 million Americans were fully vaccinated. Nationwide, more than 670,000 people have died of Covid-19.

Data on boosters from Modern and Johnson & Johnson is expected in the coming weeks, said Fauci. He also said “This Week” that there will “certainly” be a vaccine for children this fall.

FDA panel recommends Pfizer’s Covid booster doses for individuals 65 and older

An influential advisory committee to the Food and Drug Administration on Friday rejected a proposal to distribute booster vaccinations from Pfizer and BioNTech Covid-19 Vaccine to the general public and scaled back those plans, unanimously recommending the third vaccination to people 65 and older and other at-risk Americans.

“In my opinion it is likely to be beneficial for the elderly and eventually could be indicated for the general population. I just think we’re not there yet in terms of the data, ”said Dr. Ofer Levy, a vaccine and infectious disease specialist at Boston Children’s Hospital.

The panel voted 16-2 against distributing the vaccines to Americans 16 and older before unanimously adopting an alternative plan to give boosters to older Americans and those at high risk of developing serious illness if they got the virus receive. This previously included people with diabetes, heart disease, obesity and other so-called comorbidities.

Pfizer stock closed 1.3% while BioNTech’s shares fell 3.6%.

The non-binding decision of the FDA’s Advisory Committee on Vaccines and Related Biological Products comes as the Biden government announced that it would begin offering booster vaccinations to the general public as early as next week pending approval from US health regulators . Although the agency has not always followed the advice of its committee, it often does. A final FDA decision could be made in a matter of hours. The Centers of Disease Control and Prevention has scheduled a two-day meeting next week to discuss plans to distribute the third syringes in the United States

“We’re not tied to your voice at the FDA just for you to understand. We can adjust this as needed,” recalled Dr. Peter Marks, the agency’s top vaccine regulator, joined the panel after the votes. He asked the group for suggestions on what other populations the FDA should consider for boosters, such as frontline health workers and other professions exposed to higher levels of exposure to Covid.

It was expected that the committee vote would be controversial, as some scientists included two senior FDA Officials involved in Friday’s meeting said they were not entirely convinced that every American who received the Pfizer vaccine now needs extra doses.

White House senior medical advisor Dr. Anthony Fauci said he wasn’t surprised they didn’t recommend the shots for anyone 16 and older. Fauci, who publicly supported Booster, hesitated in an interview on Friday “Closing bell“To guess what the committee would ultimately decide.

“I don’t want to pre-empt the advisory committee at the time they are deliberating,” he said.

Liesl Eibschutz, a Dartmouth University medical student, loads a syringe of Pfizer COVID-19 vaccine before giving the vaccine on the first day people 16 and older get the vaccine at Kedren Health on Thursday, Angeles, California.

Allen J. Cockroaches | Los Angeles Times | Getty Images

In published a paper Days before the advisory committee meeting, a leading group of scientists said the available data showed that vaccine protection against serious illnesses persists, even as efficacy against mild illness wears off over time. The authors, including two senior FDA officials and several World Health Organization scientists, argued Monday in the medical journal The Lancet that widespread use of booster syringes to the general public is currently inappropriate.

In the outlines of the plans for last month’s launch Distribute booster next week, Biden administration officials cited three CDC studies showing that vaccine protection against Covid has waned over several months. Senior health officials said at the time they feared protection from serious illnesses, hospitalizations and deaths could “wear off” in the coming months, especially for those at higher risk or vaccinated during the earlier stages of vaccination.

Before the vote, some committee members said they were concerned that there wasn’t enough data to make a recommendation, while others argued that the third shot should be limited to specific groups, e.g. illness. Some members raised concerns about the risk of myocarditis in younger people and said more research was needed.

Dr. Hayley Gans, a voting member, said she was “concerned” that the FDA asked the committee to review the entirety of the evidence presented Friday because some data, including on safety, were still inadequate.

Another member, Dr. Paul Offit said he would support boosters for people over 60 but struggled to support a third vaccination for younger groups due to a higher risk of myocarditis.

Ahead of Friday’s vote, the committee listened to several presentations on data supporting the widespread use of booster vaccinations, including by health officials in Israel, where officials began vaccinating the country’s population before many other countries and their citizens later July.

Phil Krause, an FDA vaccine regulator and co-author of The Lancet, criticized the results presented Friday, saying that much of the data had not been federally vetted or peer-reviewed. He said the models used are complex and scientists need to make sure they are “getting the right results.”

“That’s part of the difficulty of looking at this type of data without a way for the FDA to review it,” he said.

In documents released by the FDA on Wednesday, Pfizer said an observational study in Israel showed that a third dose of the Covid vaccine restored infection protection to 95% six months after a second vaccination. The data was collected from July 1 to August 30, when the rapidly expanding delta variant emerged across the country.

In a presentation on Friday, Dr. Sharon Elroy-Price of the Israeli Ministry of Health said that if officials there had not started distributing boosters in late July, the country would likely have exceeded its hospital capacity. Health officials began to see a trend that people in their 40s and 50s who were fully vaccinated became seriously ill with Covid.

“We didn’t want to wait for these results and we knew we had to vaccinate a larger section of the population to get the numbers down quickly,” she told the committee. Israeli health officials expected an average of 2,000 serious cases by the end of August, she said. “We have been able to dampen this effect and our severe cases are around 700 or less and have remained stable even though we still have days with 10,000 confirmed cases.”

She also said the booster was well tolerated by many people, citing data showing that out of approximately 2.9 million people who received the additional doses, there was only one case of myocarditis, a rare inflammation of the heart that occurred with mRNA vaccines.

Pfizer’s booster side effects are also similar to those seen after receiving the second dose of vaccine, said Dr. Joohee Lee, an officer with the FDA’s Office of Vaccines Research and Review, during the meeting.

Of the 289 booster recipients, ages 18 to 55 years old, observed in Pfizer’s Phase 3 study, 63.8% developed fatigue, 48.4% headache, and 39.1% muscle pain. The FDA examined side effects in 2,682 recipients of Pfizer’s second dose of Covid aged 16 to 55 years and reported fatigue in 61.5% of patients, headache in 54%, and muscle pain in 39.3%. One adverse event – swelling of the lymph nodes – occurred in 5.2% of booster recipients but only 0.4% of those who received their first two doses.

“The majority were mild to moderate and they resolved,” Lee said of the lymphadenopathy cases. “Though one is reported to be underway right now.”

CDC panel debates want for Covid vaccine booster pictures

[The stream is slated to start at 10 a.m. ET. Please refresh the page if you do not see a player above at that time.]

A key advisory group from the Centers for Disease Control and Prevention meets Monday to consider booster coverage of Covid-19 vaccines for all eligible Americans.

The meeting of the Advisory Committee on Vaccination Practices of the CDC takes place after President Joe Biden. instead of said Friday US regulators are considering giving Covid booster vaccinations five months after completing the primary series and bringing forward the expected schedule for a third vaccination by three months.

Scientists have sharply criticized The Biden government’s urge to distribute booster syringes widely says the data provided by federal health officials are not compelling enough to currently recommend third vaccinations for most of the American population.

The Biden administration has publicly stated that the third dose will not be carried out without FDA approval and a vote by ACIP.

The advisory group is also due to vote on Monday on the full approval of Pfizer’s Covid vaccine for Americans 16 and older.

PASSHE chancellor floats $75 million plan for one-time cash at state Senate panel

  • Sam Darklau

    Sam Dunklau is the head of the Capitol Bureau for WITF. He previously reported on the Illinois government for NPR member station WUIS in Springfield, IL.

    Sam has been floating through the radio waves as a reporter, disc jockey and station manager since 2015. He grew up in the small town of Paw Paw, Illinois, in the Midwest and is a proud graduate of Augustana College.

July 21, 2021 | 4:09 pm

(Harrisburg) –– The group leader of 14 Pennsylvania state universities details how he plans to spend $ 75 million, primarily federal, on pandemic aid over the next year.

About two-thirds of this is federal funds intended to help the group of 14 universities recover from the coronavirus pandemic. The remainder are savings recently realized by the system by refinancing the pension debt it owes to the state employee pension system.

Chancellor of the state higher education system, Daniel Greenstein, shared a draft of the plan with a state Senate committee Tuesday when he answered Senators’ questions about the upcoming merger of Bloomsburg, Lock Haven and Mansfield Universities into a rooftop school and California, Clarion and Edinboro Universities in another.

The system’s board of governors voted unanimously last week to continue these mergers and plans to introduce the new “integrated” Western film and northeast Higher education systems next July.

“This was really the beginning of a journey, not the end of one, and it will take continued commitment … as we build two regional education centers,” Greenstein said in his opening comments to Senators.

Greenstein’s ideas about spending the one-time cash seemed to reflect that reality. He suggests spending $ 15 million of the money on doing the integrations, but also wants to spend other portions of it to make PASSHE schools more attractive in a post-pandemic world.

PASSHE / via Pa. State Senate Livestream Video

A screenshot from a presentation by PASSHE Chancellor Dan Greenstein to the Pennsylvania Senate on July 20, 2021 showing a proposed spending plan for a cash inflow of $ 75 million, the majority of which is to help the university system get out of the pandemic to recover.

“The students returning from the pandemic will be different from those before her in terms of their expectations and the type of learning experience,” Greenstein said. “Universities and colleges in general will do well to watch out for these changing patterns of behavior.”

Greenstein also wants to use part of the money to help schools pay off their debts in building and renovating less-used dormitories. Enrollment in PASSHE schools across the board has declined 20 percent since its peak in 2011which means fewer students will need on-campus accommodation.

He pointed out to state senators that while schools are exploring new ways to use these buildings, the system may need to sell them to save money. It looks like PASSHE’s three soon-to-be-merged universities in the west will collectively lose millions of dollars over the next few years as consolidation efforts continue.

“There are many uses [for] Dormitories, ”said Greenstein. “But this alternative takes a while to establish itself. It’s not a slam dunk, let’s put it that way. “

PASSHE’s Board of Governors is expected to consider a more detailed spending plan for the extra money in October.

Home panel advances Randolph well being heart mission cash

RANDOLPH – The U.S. House of Representatives Committee on Budgets has submitted a series of expense bills totaling nearly $ 1.4 million for projects in Randolph and Milton.

The projects, proposed by the community and drafted into legislation by US MP Ayanna Pressley, call for $ 1 million to build a community health center at Randolph High School and $ 275,000 for more culturally appropriate educational materials at Randolph Public Schools. A $ 100,000 Milton proposal provides a data-driven curriculum and professional development for the city’s teachers to fill the math and reading gaps exacerbated by the pandemic.

“COVID-19 has exposed the severe inequalities in our public health and education systems, particularly in hard-hit communities like Randolph and Milton,” Pressley said in a statement. Funding for these three projects would help provide the accessible, trustworthy, and experienced health services the residents of Randolph need while providing our most vulnerable students in Randolph and Milton with high quality, culturally sensitive education that will guide them College and prepared for their careers. Selection.”

More: Proposed Condos on Randolph Avenue Makes 8 Active 40 Billion Proposals in Milton

More: Randolph Receives an Additional $ 21 Million in COVID-19 Aid

The Budget Committee passed 12 spending bills that will be presented to plenary starting this week before moving to the Senate if passed. Funding of the local projects is not guaranteed even if the actions happen through the house. Congressmen and lawmakers expect the bills to be the basis for negotiations with Senate lawmakers on a possible year-end bulk spending bill, for example.

Local officials have long kept an eye on a health center in Randolph and praise the efforts.

“The health center issue is not new,” said Alderman Ken Clifton last month when Prssley was meeting with local officials. “It’s clear you need one. The pandemic has really increased the need for such a facility.”

Randolph Town Manager Brian Howard said the town needs a health center.

“This much-needed school health center will make an immeasurable contribution to the health of Randolph’s youth and families,” Howard said in a statement. “Randolph’s inadequate health care was acutely evident during the COVID pandemic, when Randolph was a hot spot. This new health center in Randolph’s High School will build our local health infrastructure and increase our ability to meet health care needs and be better prepared for crises. ”

More: A native of Randolph, he is a stunt double on “Without Remorse” and other local entertainment news

More: Keenan: More Affordable Care Act looks at lessons learned from the pandemic

James Jette, superintendent of Milton Public Schools, said he was grateful that Pressley wanted to help students end learning disrupted by the pandemic.

Pressley’s proposals are part of an initiative to fund community projects by the US Home Funds Committee. Project funding is a newer, more accountable version of what was formerly known as “earmarks” to channel federal funds towards specific projects in a congressman’s district.

The new round of spending bills is separate from an infrastructure bill passed by the House of Representatives earlier this month.

Material from The Detroit News, part of the USA Today Network, was used in this report.

Many thanks to our subscribers who make this reporting possible. If you are not a subscriber, please consider supporting quality local journalism with a Patriot Ledger subscription.

Joe Difazio can be reached at Follow him on Twitter @jldifazio.

School Gamers Could Make Cash Off Their Fame, Highly effective N.C.A.A. Panel Recommends

Leader of the NCAA, the most influential umbrella organization in university sports, existed for months that they are keen to move forward with new guidelines to provide players with greater economic opportunities. And while many athletics leaders pushed the 115-year-old federation to relax its long-standing restrictions, the college sports industry now acts largely because it had little choice.

In Alabama, Florida, Georgia, Kentucky, Mississippi, New Mexico, Ohio, and Texas, laws or executive orders will go into effect Thursday that will allow college athletes to make money using their names, pictures, and likeness. More than a dozen other states have adopted similar measures with later entry into force. But Congress got in a setback to the NCAA no agreement reached to override state laws and write a standard in federal law.

While many administrators still hope that the federal government will act at some point, the plethora of state laws – often denounced as “patchwork” by athletics officials – threatened to create an immediate imbalance in college sports. Schools in states with legal guarantees that students could potentially make money, the argument goes, would be better positioned to recruit potential players and would draw the greatest future talent to a handful of schools. The NCAA’s decision to intervene, executives hope, will avert the worst possible inequalities, at least for a short time.

Still, the road to Monday’s recommendation was speckled with internal fighting, caution, threats and last-minute maneuvers. No recent development has been more momentous than the Supreme Court ruling last week, which undermined the NCAA’s approach to antitrust law and urged the industry to give athletes more rights than top executives once expected.

The NCAA v Alston case was closely focused on educational benefits such as academic awards and paid internships, but the court’s unanimous ruling removed some of the legal precedents that the association and its members had relied on for decades for protection. The decision unnerved college sports officials, many of whom were already drained by seemingly endless legal battles, and heightened concerns that a string of tough NCAA name, image, and likeness rules would create more legal challenges and perhaps even more pronounced defeats .

Advertising society panel options Uber’s Head of Leisure and Cultural Advertising | LIFE+ARTS

LMU’s Marketing Society hosted a panel on Wednesday April 14th with Benjamin Trinh – Uber’s global director of entertainment and cultural marketing. This panel is part of the Marketing Society’s guest speaker series and was moderated by the Society’s Co-President Natalie Robles.

The event began with Robles asking Trinh to speak about his career and provide background information about himself. Speaking of his career, he said, “The goal of my team at Uber is to drive the brand towards culture.” Trinh then spoke about his personal life, mentioning that he was from Oakland, California and graduated from UC Davis. He then lived in several cities before finally settling in LA

Trinh decided to call LA his home because “Los Angeles makes a lot of sense to me because my career has been at the intersection of entertainment and technology and LA is the entertainment capital of the world.” Afterward, Robles stated that attendees could ask questions by unmuting or dropping their questions into the zoom chat box.

Most of the attendees asked questions about Trinh’s profession, college activities, advice for college students, and digital marketing. Among the details he revealed included that Uber has a big campaign ahead of them to put themselves at the forefront of the next Olympics, and that Postmates is currently working with a well-known celebrity to create a limited edition Shake Shack burger to create.

When asked why such panels would benefit business students, Francesca Diolanto, major in entrepreneurship, replied, “It would benefit students because they could link the knowledge they receive in school to a real-life example. This event is also beneficial because it helps students better understand the type of business field they are trying to enter. In this case, it is the grocery delivery business. “

Marina Deguchi, a freshman in business administration, replied, “I’ve been to many Marketing Society events and can keep in touch with the panelist afterwards. They will say, ‘Here is my username; You can contact me on LinkedIn. “” She continues, “I think this is very beneficial for networking, which helps business students in many ways.”

Overall, Diolanto and Deguchi emphasized the importance of networking and learning about certain business areas in their answers. They say the panel was very engaging and personal because of its informal and open nature. The ethos of the event was similar to that of a division at a daytime show. The students found it very informative for students looking to pursue careers in digital marketing.

CDC panel postpones pause determination

Pharmacist Madeline Acquilano vaccinates a teacher with the Johnson & Johnson Covid-19 vaccine at Hartford Hospital in Hartford, Connecticut on March 3, 2021.

Joseph Precious | AFP | Getty Images

A panel of the Centers for Disease Control and Prevention decided on Wednesday to postpone a decision on Johnson & Johnson’s Covid-19 vaccine after six women developed a rare but potentially life-threatening bleeding disorder that left one dead and critical Condition left behind.

The CDC’s Advisory Committee on Immunization Practices met the day after the Food and Drug Administration States requested temporarily “Out of caution”, stop using J & J’s vaccine. The panel unanimously voted to meet in a week’s time to decide what to recommend to the CDC about J & J’s vaccine. The postponement means the pause for J & J’s vaccine will remain in place.

The committee debated whether and how long they wanted to continue the hiatus on J & J’s vaccine while the CDC investigates the cause of the clotting. One committee member recommended a month’s hiatus from restarting vaccinations, while other members recommended a few weeks. Some members asked if they could hold the vote on hold until they had more time to process the data.

One of the options the panel considered was whether to recommend restricting vaccine use based on age or other risk factors.

Dr. Grace Lee, a member of the committee, said she feared a vote to suspend the use of the vaccine indefinitely would send the wrong message to the public. She and others added it might appear that something is fundamentally wrong with the vaccine.

“This is not the decision that I think makes the most sense,” she said.

Sandra Fryhofer of the American Medical Association advocated taking a break. She said there are enough supplies of Moderna and Pfizer vaccines to keep the rapid vaccinations going in the US

“I know there are a lot of patients who couldn’t be vaccinated and need to be vaccinated, but we want to make sure these vaccines are safe,” she said.

Dr. Nirav Shah, the director of the CDC in Maine, said the committee’s vote to postpone a decision on how to use the vaccine was “equivalent to a decision”.

“Any extension of the hiatus will invariably result in the most vulnerable people in the US, who were the lead candidates for the J&J vaccine, remain at risk. The most at risk remain at risk.”

The CDC and FDA advised states to postpone appointments for J&J vaccines after six women developed cerebral sinus thrombosis (CVST) within about two weeks of receiving the shot, U.S. health officials told reporters Tuesday. CVST is a rare form of stroke that occurs when a blood clot forms in the venous sinuses of the brain. It can eventually leak blood into the brain tissue and cause bleeding.

“CVST is rare but clinically severe and can lead to significant morbidity and mortality,” said Dr. Tom Shimabukuro, a CDC official, told the committee. He said CVST cases in the J&J vaccine group appeared to be three times higher than in women aged 20 to 50 with similar backgrounds.

Within hours of the FDA’s warning early Tuesday, more than a dozen states as well as some national pharmacies did suspended vaccinations With the J&J vaccine, some are replacing scheduled appointments with either the Pfizer or Moderna vaccine.

U.S. health officials had said the break in using the vaccine could only be a few days, depending on what they learned when investigating the cases. The Chief Medical Officer of the White House, Dr. Anthony Fauci said Tuesday the hiatus in vaccine use would give U.S. health officials a chance the time it takes them to thoroughly investigate the cases and “find some common denominator among the women who were involved.”

A 25-year-old male developed CVST along with bleeding during the clinical trial who was hospitalized but recovered. All six cases that appeared after the clinical trial were found in white women, Shimabukuro said, noting that the median time to symptoms was eight days. Three were described as obese, one had hyperthyroidism, one had asthma, and one had high blood pressure, he said.

Five of the six patients developed headaches initially and one had back pain and bruising before developing more serious other symptoms, he said. One of the women died. Three of the patients are staying in the hospital while two have been discharged, he said.

“These are significant blood clots that are causing these problems,” he said.

Dr. Aaran Maree, chief physician of the vaccines division at J&J, Janssen Pharmaceutical Cos., Told the committee that none of the women had birth control, which has been suggested as a possible association with blood clotting. They all also tested negative for Covid-19.

One of the two patients who recovered was a 26-year-old woman who was described as “overweight but active”, who was not on medication, and had no history of bleeding disorders.

She was hospitalized and discharged with a severe headache a week after receiving the J&J vaccine, but returned to the hospital a week later with abdominal pain and a fast heart rate, he said. Tests showed that she developed thrombocytopenia and CVST.

A 48-year-old woman with an “unremarkable medical history” was admitted to the hospital after three days with malaise and abdominal pain. She developed severe thrombocytopenia and CVST which, despite treatment with the blood-thinning heparin, progressed to a hemorrhagic stroke. She received the J&J vaccine two weeks before symptoms began and is still critically ill, according to the latest report.